Arrowhead Pharmaceuticals Inc (ARWR)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$68.21
Buy
$70.00
$-0.73 (-1.03%)
Prices updated at 13 Dec 2025, 00:51 EST
| Prices minimum 15 mins delay
Prices in USD
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 4m | 829m | |
| - | - | |
| -601m | 98m | |
| -16,927.06 | 11.86 | |
| -599m | -2m | |
| -562m | 165m | |
| Sales, General and administrative | 97m | 122m |
| Interest expenses | 32m | 89m |
| Provision for income taxes | -3m | 21m |
| Operating expenses | 605m | 731m |
| Income before taxes | -612m | 52m |
| Net income available to common shareholders | -599m | -2m |
| -5.15 | -0.01 | |
| Net interest income | -10m | -52m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -5.15 | -0.01 |
| Free cash flow per share | -5.0451 | -0.1344 |
| Book value/share | 1.4768 | 3.849 |
| Debt equity ratio | 2.718934 | 0.684462 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 695m | 951m |
| Current liabilities | 103m | 195m |
| Total capital | 579m | 681m |
| Total debt | 511m | 366m |
| Total equity | 185m | 466m |
| Total non current liabilities | - | - |
| Loans | 393m | 215m |
| Total assets | 1,140m | 1,385m |
| Total liabilities | - | - |
| Cash and cash equivalents | 103m | 89m |
| Common stock | 124m | 136m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 111m | 103m |
| Cash dividends paid | - | - |
| -604m | 157m | |
| Investments (gains) losses | -420m | -129m |
| 103m | 227m | |
| Net income | - | - |
| -463m | 180m | |
| -141m | -23m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
